ScholarIQanswers from OpenAlex & ORCID
Stefan Hantel
ResearcherPublications, citations & collaboration network
Stefan Hantel is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Stefan Hantel have?
ScholarIQindexed works
Stefan Hantel has 109 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Stefan Hantel have?
ScholarIQcitation count
Stefan Hantel has 20,827 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Stefan Hantel?
ScholarIQh-index
Stefan Hantel has an h-index of 34 in OpenAlex.
What is the i10-index of Stefan Hantel?
ScholarIQi10-index
Stefan Hantel has an i10-index of 47 in OpenAlex.
What is the OpenAlex record for Stefan Hantel?
ScholarIQopenalex
The OpenAlex for Stefan Hantel is on the source record.
What are the most-cited papers on Stefan Hantel?
ScholarIQmost cited works
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Silvio E. Inzucchi
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME <sup>®</sup> trial
David Fitchett, Bernard Zinman, Christoph Wanner, John M. Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J. Woerle, Uli C. Broedl, Silvio E. Inzucchi
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T. George, Stefan Hantel, Erich Bluhmki, John M. Lachin
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
David Fitchett, Javed Butler, Philippe van de Borne, Bernard Zinman, John M. Lachin, Christoph Wanner, Hans J. Woerle, Stefan Hantel, Jyothis T. George, Odd Erik Johansen, Silvio E. Inzucchi, the EMPA-REG OUTCOME® trial investigators
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
Christoph Wanner, Hiddo J.L. Heerspink, Bernard Zinman, Silvio E. Inzucchi, Audrey Koitka‐Weber, Michaela Mattheus, Stefan Hantel, Hans‐Juergen Woerle, Uli C. Broedl, Maximilian von Eynatten, Per‐Henrik Groop, on behalf of the EMPA-REG OUTCOME Investigators